The U.S. Meals and Drug Administration on Tuesday accredited Reata Prescribed drugs Inc.’s remedy for Friedreich’s ataxia, a uncommon inherited illness that causes injury to the nervous system.
Reata’s RETA inventory was halted in after-hours buying and selling on Tuesday upfront of the FDA’s determination.
The drug, omaveloxolone, which is now known as Skyclarys,…
